Syracuse University

Regis University

Managing Director, PSG Life Sciences

PSG Life Sciences, part of the Princeton Solutions Group of Companies,   is a management consulting firm advising companies on issues of sales, marketing and business development strategy, operations and tactical execution. We work with domestic and international companies selling into the Biomedical, R&D and Clinical Diagnostic markets (Academic, Global Pharmaceutical, Biotech and Government, etc.). PSG Life Sciences has helped companies, their salespeople, and executive teams develop strategy, process, and skills to improve sales productivity and top-line growth. Unlike alternatives, we offer a unique performance based consulting model that guarantees results.

PSG Life Sciences works with our clients  to improve their strategy, processes and execution to accelerate revenues. We create custom solutions with our customers to meet and exceed their  Sales, Marketing, Business Development and Channel/Distributor revenue goals.

PSG Life Sciences provides our clients with answers to their most critical problems related to revenue retention and growth. Competition and market dynamics require sales, marketing and business development efforts to be three steps ahead of the competition. At PSG Life Sciences, we have first hand experience in driving double digit growth in the most competitive global markets. We bring our experience and proven methodologies to help clients create and sustain a competitive advantage.

PSG Life Sciences

Managing Director

Impacting the research, diagnosis and treatment of human diseases through our novel antibody discovery and optimization platform.

The company is founded on the scientific understanding of hypermutation in yeast, our experience in yeast biology and immunology. In immunized animals, somatic hypermutation plays a leading role in antibody maturation by generating point mutations in the V genes, which provides high-affinity antibodies required for the affinity maturation process. To bring revolutionary speed and diversity to antibody generation, Abzyme Therapeutics developed yeast-based technology platforms mimicking mammalian antibody diversification and affinity maturation processes. As this is an animal-free in vitro system, we are able to develop antibodies not only to conventional targets but also to a variety of difficult targets including non-immunogenic and highly toxic antigens or cell surface antigens.

Unique to Abzyme is our proprietary eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody maturation, and 

Abzyme Therapeutics provides comprehensive custom recombinant antibody discovery and development platform services. Our service offerings include antigen and project design, antibody discovery, antibody optimization, antibody production, and SPR-based antibody characterization. Our Recombinant Antibody Development programs comprise single domain camelid (VHH) and human (VH) antibodies, human ScFv and IgG antibodies and rabbit monoclonal antibodies. Abzyme offers endotoxin-free antibody production services for recombinant antibodies using bacterial expression systems as well as mammalian expression for customers concerned about glycosylation. Production scales from 250 ml to 100 L are within our standard capabilities.

Abzyme Therapeutics

Director of Business Development (Consultant)

Professional Staffer Services

Global Account Manager

Kingston Volunteer Fire Company

Treasurer

Stephen Manobianco is the Vice President, Global Sales and Business Development at GENEWIZ, LLC. Before joining GENEWIZ a little over five years ago, in full-time executive leadership position, he had been a strategic advisor for the previous eight years. For the first several years with GENEWIZ he lead the expansion of the US Sales and Marketing Teams driving double digit year over year revenue growth.

Stephen's current focus is on leading the company's international expansion and expanding their genomic services platform into new markets such as the clinical trial space. As the company’s Business Development Executive he is responsible for identifying and negotiating commercial collaborations and Private Public Partnerships. He is also the member of the leadership team responsible for the company’s European and Japan sales and business development efforts and personnel. In this role, with the recent acquisition of Beckmann Coulter Genomics, he successfully led the integration of the two European sales organizations. 

GENEWIZ is a contract research organization (CRO) specializing in DNA-based services including Next Generation Sequencing, Sanger sequencing, gene synthesis, molecular biology, and GLP/cGMP regulatory services. The company is the world’s largest commercial sequencing company and leads the industry in outsourcing partnerships with pharmaceutical, clinical, biotechnology, academic, and government institutions. Headquartered in South Plainfield, NJ, GENEWIZ is a global enterprise with l laboratory sales office locations in Boston, San Francisco, Seattle, RTP, Los Angeles, San Diego, Washington D.C. Metro, Takeley U.K., Suzhou, China, and Beijing, China.

Steve Manobianco